SCHEMBL23970755

SCHEMBL23970755

CC(C)(C)OC(=O)c1ccncc1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
KDM4E B2RXH2 2/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
CCNC P24863 1/20 0.37
CDK8 P49336 1/20 0.37
RAB9A P51151 2/20 0.37
ATR Q13535 1/20 0.37
KDM4C Q9H3R0 3/20 0.37
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
L3MBTL1 Q9Y468 2/20 0.36
KDM6B O15054 1/20 0.36
KDM4A O75164 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
KDM4D Q6B0I6 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31203260 0.87 ALDH1A1 (0.39) ALDH1A1KDM4EGLAGAACCNC
SCHEMBL26127199 0.87 ALDH1A1 (0.39) ALDH1A1KDM4EGLAGAACCNC
SCHEMBL26132704 0.81 ALDH1A1 (0.44) ALDH1A1KDM4EGLAGAARAB9A
SCHEMBL359044 0.81 KDM4E (0.64) ALDH1A1KDM4EGLAGAACCNC
SCHEMBL29574489 0.81 KDM4E (0.64) ALDH1A1KDM4EGLAGAACCNC
SCHEMBL31364268 0.80 KDM4C (0.47) ALDH1A1KDM4EGLAGAAATR
SCHEMBL31487718 0.80 ALDH1A1 (0.68) ALDH1A1KDM4EGLAGAARAB9A
SCHEMBL17820387 0.80 KDM4E (0.42) ALDH1A1KDM4EGLAGAARAB9A
Hydrochloric Acid SCHEMBL2900807 0.79 KDM4E (0.62) ALDH1A1KDM4EGLAGAACCNC
SCHEMBL30181099 0.79 ALDH1A1 (0.57) ALDH1A1KDM4EGLAGAARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11976083-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2024-05-07 US disclosed
CN-115551862-B Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2024-04-12 CN disclosed
EP-4143189-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2023-03-08 EP disclosed
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. 2023-01-05 US disclosed
CN-115551862-A Macrocyclic inhibitors of peptidyl arginine deiminase 吉利德科学公司 2022-12-30 CN disclosed
WO-2021222353-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2021-11-04 WO disclosed
WO-2021222353-A1 MACROCYCLIC INHIBITORS OF PEPTIDYLARGININE DEIMINASES GILEAD SCIENCES, INC. (US) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11976083-B2 Inhibitors of peptidylarginine deiminases PADI4, PADI2, PADI1 ALDH1A1 2537/4885KDM4E 936/4885GLA 3177/4885
US-20230002412-A1 INHIBITORS OF PEPTIDYLARGININE DEIMINASES PADI4, PADI2, PADI1 ALDH1A1 2537/4885KDM4E 936/4885GLA 3177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.